Spotlight on Hematology

Credits: 1.0 CME / CNE / CPE
Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies
Steven P. Treon, MD, MA, PhD
Rush University Medical Center

Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Hematology Presentations

Jennifer Woyach, MD
0.5 CME
Postgraduate Institute for Medicine
Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting

Podium to Practice: Clinical Updates for the Treatment of Patients with CLL from the 2021 Annual Hematology Meeting

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 1, 2022
Expires: February 1, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review how patient and disease-related factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
  • Evaluate recent clinical trial data on the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
  • Assess various approaches to the treatment of patients with relapsed/refractory CLL, including the optimal sequencing of agents

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two chronic lymphocytic leukemia (CLL) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

With an age‐adjusted incidence of 4.1/100,000 inhabitants in the United States, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The natural history of CLL is variable, and outcomes are influenced by multiple patient and disease-related factors. Given the heterogeneity of the disease, there is no “one size fits all” recommendation. Clinicians need to be aware of the multiple patient and disease-related factors that impact selection of therapy for patients with CLL and need expert guidance on the selection of optimal frontline treatment approaches for their patients with CLL.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Jennifer Woyach, MD

The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Consultant: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Morphosys, and Pharmacyclics
Contracted Research: AbbVie, Karyopharm, Loxo, Morphosys, and Verastem


Matthew S. Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consultant: Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lily, Genentech, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 1, 2022
Expires: February 1, 2023
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review how patient and disease-related factors such as patient age, performance status, comorbidities, and mutational status impact the choice of therapy for patients with CLL
  • Evaluate recent clinical trial data on the safety and efficacy of current and emerging agents and regimens for patients with newly diagnosed CLL
  • Assess various approaches to the treatment of patients with relapsed/refractory CLL, including the optimal sequencing of agents

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two chronic lymphocytic leukemia (CLL) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.

Statement of Educational Need

With an age‐adjusted incidence of 4.1/100,000 inhabitants in the United States, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in western countries. The natural history of CLL is variable, and outcomes are influenced by multiple patient and disease-related factors. Given the heterogeneity of the disease, there is no “one size fits all” recommendation. Clinicians need to be aware of the multiple patient and disease-related factors that impact selection of therapy for patients with CLL and need expert guidance on the selection of optimal frontline treatment approaches for their patients with CLL.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator
Jennifer Woyach, MD

The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Consultant: AbbVie, Arqule, AstraZeneca, BeiGene, Janssen, Loxo, Morphosys, and Pharmacyclics
Contracted Research: AbbVie, Karyopharm, Loxo, Morphosys, and Verastem


Matthew S. Davids, MD, MMSc
Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consultant: Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lily, Genentech, Janssen, Merck, Ono Pharmaceuticals, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, Verastem, and Zentalis
Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Pages